Indobufen Versus Aspirin in Endovascular Unruptured Intracranial Aneurysms Treatment
This project aims to evaluate the safety and efficacy of the antiplatelet regimen combining indobufen and clopidogrel in preventing ischemic events after stent-assisted coiling embolization and flow diverter implantation for intracranial aneurysms. Using a randomization system, patients with unruptured intracranial aneurysms scheduled for interventional treatment will be divided into an experimental group and a control group. Patients in the experimental group will be required to take indobufen (100 mg twice daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively. Patients in the control group will be required to take aspirin (100 mg once daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively. An independent group of researchers will assess cerebrovascular thromboembolic events and bleeding events at different time points.
• Age 18-75 years (male or female);
• Radiologically confirmed saccular intracranial aneurysm (by specialist assessment);
• Scheduled for endovascular embolization (including: coil embolization with stent assistance or flow diversion);
• Signed informed consent obtained.